ClinicalTrials.gg
Not yet recruitingNCT06943911BC-CHATUpdated Apr 25, 2025

Reflects the Intervention (AI Chatbot)

An interventional study of AI Chatbot for Breast Cancer Patient Education and Empowerment in Breast Cancer Early Stage Breast Cancer (Stage 1-3), sponsored by Mostafa Shaban. Not yet recruiting at 1 site in Egypt. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-25.

Sponsored by Mostafa Shaban · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 248 studies in Breast Neoplasms with a site in Egypt — 58 open to participants now, 68 under way, 5 of them phase 3. Breast Neoplasms · Egypt.

Planned enrollment
42nd of 183
122 · median 70
Started
2025
with 24 others
No phase
85 of 248
22 open now
Primary completion
2025-07
later than 20 of 67 live
Registered
200th of 248
by date

Among the 248 studies in Breast Neoplasms with a site in Egypt, this one is the 42nd largest by planned enrollment of the 183 interventional ones that give a count, is one of 25 that started in 2025, is one of 85 with no phase, reaches primary completion later than 20 of the 67 other live ones, and was the 200th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

58 of the 248 studies in Breast Neoplasms with a site in Egypt are open now. Recruiting first, the newest first:

53 more — sign in →

All 58 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 248 studies in Breast Neoplasms with a site in Egypt, or all of them as a file.
02

Study summary

The goal of this clinical trial is to investigate the impact of an AI-powered chatbot intervention on improving knowledge, attitudes, and empowerment in breast cancer patients. The study focuses on female breast cancer patients, aged 18 years or older, who are receiving treatment at Kafr El-Sheikh University Hospital in Egypt.

The main questions it aims to answer are:

Can the AI chatbot intervention improve breast cancer knowledge compared to standard care?

Can the AI chatbot intervention positively influence attitudes toward AI in healthcare?

Does the AI chatbot intervention enhance patient empowerment in managing breast cancer?

Researchers will compare:

Intervention group (AI chatbot + standard care) to control group (standard care alone) to see if the AI chatbot intervention leads to greater improvements in knowledge, more positive attitudes towards AI, and higher perceived empowerment.

Participants will:

Engage with an AI-powered chatbot designed to provide personalized education on breast cancer, treatment options, and emotional support.

Complete pre- and post-intervention assessments to measure changes in knowledge, attitudes toward AI, and empowerment.

Receive standard care, including routine oncology consultations and nursing support, alongside the chatbot intervention (for the intervention group).

Read the detailed description

This study explores the integration of AI-powered chatbots in breast cancer care to enhance patient education, self-management, and psychosocial support. Breast cancer is often accompanied by a range of psychological challenges, including anxiety and uncertainty about treatment options, side effects, and overall prognosis. Traditional healthcare systems struggle to provide continuous support, which is where AI technology can offer a solution by enabling 24/7 access to information and emotional support.

The study design employs a quasi-experimental approach, where 122 breast cancer patients were recruited from Kafr El-Sheikh University Hospital. Participants were randomly assigned to one of two groups:

Intervention Group (n=61): Participants in this group received standard care, which includes routine consultations with oncology specialists and nurses, in addition to an AI chatbot intervention. The chatbot delivered personalized educational content about breast cancer, treatment options, and self-care. It also offered emotional support by answering queries and providing motivational messages.

Control Group (n=61): Participants in this group received only standard care, which consisted of regular oncology consultations and nursing support without the chatbot.

The AI chatbot intervention is designed to:

Improve knowledge about breast cancer, treatment side effects, symptom management, and emotional well-being.

Foster positive attitudes toward AI in healthcare by providing a reliable, non-judgmental source of information.

Enhance empowerment by allowing patients to actively engage with their care information outside of regular hospital visits.

Participants' knowledge, attitudes toward AI, and empowerment were assessed at two time points:

Baseline (before the intervention)

Post-intervention (after 4 weeks of engaging with the chatbot)

The primary outcome of the study is to evaluate improvements in breast cancer-related knowledge, measured through a questionnaire that assesses knowledge in key areas such as early detection, treatment options, side effects, and AI's role in healthcare. The secondary outcomes focus on attitudes toward AI and perceived empowerment, assessed through validated Likert scales designed for this purpose.

This study will provide valuable insights into the feasibility and efficacy of AI-powered chatbots in enhancing patient care for breast cancer patients, especially in resource-limited settings. Furthermore, it aims to contribute to the growing body of evidence supporting the use of digital health technologies in oncology nursing and patient empowerment.

03

Conditions studied

  • Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Keywords

  • AI Chatbot
  • Breast Cancer
  • Patient Education
  • Empowerment
  • Oncology Nursing
  • Attitudes Toward AI
  • Digital Health
  • Patient Support
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Female participants diagnosed with breast cancer, regardless of cancer stage.

Age 18 years or older.

Ability to read and communicate in Arabic to interact with the AI chatbot.

Willingness to participate in the study and to engage with the AI chatbot for the duration of the intervention.

Ability to provide .

Exclusion criteria

Exclusion Criteria:

Participants with cognitive impairments or serious mental health conditions that may hinder understanding or participation in the study.

Patients currently receiving palliative care, as they may prioritize symptom management over educational interventions.

Participants who are physically unable to engage with the study's digital tools or complete assessments (e.g., due to severe illness).

Individuals who are unable to communicate in Arabic, as the AI chatbot intervention is designed in Arabic.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
122 participants (estimated)

Study arms

  • Experimental
    Intervention Group (AI Chatbot + Standard Care)

    Participants in this arm will receive standard oncology care in addition to interacting with an AI-powered chatbot. The chatbot will provide personalized educational content on breast cancer, treatment options, side effects, and offer emotional support. Participants will engage with the chatbot for 4 weeks, with assessments at baseline and post-interventi

    Behavioral: AI Chatbot for Breast Cancer Patient Education and Empowerment

  • No intervention
    Control Group (Standard Care Only)

    Participants in this arm will receive standard oncology care only, including routine consultations with oncology specialists and nurses. They will not have access to the AI chatbot intervention.

Interventions

  • BehavioralAI Chatbot for Breast Cancer Patient Education and Empowerment

    The AI Chatbot for Breast Cancer Patient Education and Empowerment is a digital health intervention that leverages artificial intelligence to provide personalized educational content and emotional support to breast cancer patients. The chatbot delivers information on breast cancer management, treatment options, side effects, and self-care practices. It is available 24/7, offering real-time answers to patient queries and tailored suggestions based on their treatment path. The aim is to increase patient knowledge, improve attitudes toward AI, and empower patients to take a more active role in their care. The chatbot intervention is provided alongside standard oncology care at Kafr El-Sheikh University Hospital.

06

What researchers measure

Primary outcomes

  1. Breast Cancer Knowledge Improvement

    This outcome measures the change in breast cancer knowledge from baseline to post-intervention for participants who used the AI chatbot compared to the control group. Knowledge is assessed using the Artificial Intelligence of Breast Cancer Questionnaire, which covers topics such as treatment options, side effects, symptom management, and AI's role in healthcare.

    Time frame: 2 months

07

Study locations

1 site
  • Faculty of Nursing Cairo University
    Cairo, Egypt
08

References and documents

Publications

  • Janopaul-Naylor JR, Koo A, Qian DC, McCall NS, Liu Y, Patel SA. Physician Assessment of ChatGPT and Bing Answers to American Cancer Society's Questions to Ask About Your Cancer. Am J Clin Oncol. 2024 Jan 1;47(1):17-21. doi: 10.1097/COC.0000000000001050. Epub 2023 Oct 12. PubMed 37823708 ↗
  • Siglen E, Vetti HH, Lunde ABF, Hatlebrekke TA, Stromsvik N, Hamang A, Hovland ST, Rettberg JW, Steen VM, Bjorvatn C. Ask Rosa - The making of a digital genetic conversation tool, a chatbot, about hereditary breast and ovarian cancer. Patient Educ Couns. 2022 Jun;105(6):1488-1494. doi: 10.1016/j.pec.2021.09.027. Epub 2021 Oct 6. PubMed 34649750 ↗
  • Agrawal A. Fairness in AI-Driven Oncology: Investigating Racial and Gender Biases in Large Language Models. Cureus. 2024 Sep 16;16(9):e69541. doi: 10.7759/cureus.69541. eCollection 2024 Sep. PubMed 39416584 ↗
  • Ma Y, Achiche S, Pomey MP, Paquette J, Adjtoutah N, Vicente S, Engler K; MARVIN chatbots Patient Expert Committee; Laymouna M, Lessard D, Lemire B, Asselah J, Therrien R, Osmanlliu E, Zawati MH, Joly Y, Lebouche B. Adapting and Evaluating an AI-Based Chatbot Through Patient and Stakeholder Engagement to Provide Information for Different Health Conditions: Master Protocol for an Adaptive Platform Trial (the MARVIN Chatbots Study). JMIR Res Protoc. 2024 Feb 13;13:e54668. doi: 10.2196/54668. PubMed 38349734 ↗
  • Chang YC, Wu CH, Lupo R, Botti S, Conte L, Vitone M, Massafra R, De Nunzio G, Vitale E. Generative Artificial Intelligence (AI) to Uncover Insights From Breast Cancer Patients' Perceptions to Mindfulness-Based Stress Reduction (MBSR) Interventions. Holist Nurs Pract. 2024 Aug 22. doi: 10.1097/HNP.0000000000000677. Online ahead of print. PubMed 39186509 ↗
  • Sato A, Haneda E, Hiroshima Y, Narimatsu H. Preliminary Screening for Hereditary Breast and Ovarian Cancer Using an AI Chatbot as a Genetic Counselor: Clinical Study. J Med Internet Res. 2024 Nov 27;26:e48914. doi: 10.2196/48914. PubMed 39602801 ↗

Individual participant data

Plan to share: Undecided — We currently do not plan to share individual participant data (IPD) outside of the research team due to concerns about participant confidentiality and the sensitive nature of the data collected. The study includes personal health information that is protected under ethical guidelines and privacy regulations. Additionally, sharing IPD may present challenges related to data security and informed consent, as participants have not explicitly consented to broader data sharing. However, the study's aggregate findings will be made publicly available through peer-reviewed publications and presentations

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2025; primary completion for Jul 2025, 2 months later.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 2 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2025
First posted
Apr 25, 2025
StartEst.
Apr 20, 2025
Primary completionEst.
Jul 1, 2025
CompletionEst.
Jul 15, 2025
Last update
Apr 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06943911
Lead sponsor
Mostafa Shaban
Responsible party
Mostafa Shaban (Dr, Cairo University) — Sponsor-investigator
First posted
Apr 25, 2025
Start date
Apr 20, 2025 (estimated)
Primary completion
Jul 1, 2025 (estimated)
Completion
Jul 15, 2025 (estimated)
Last update
Apr 25, 2025

Study contacts

Mostafa shaban, phd
Contact
mostafa.shaban2020@cu.edu.eg
+966565644617

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion